
News|Videos|December 7, 2025
Findings suggest linvoseltamab could be a useful new option for new multiple myeloma patients | ASH 2025
Author(s)Denise Myshko, Briana Contreras
Early results from the LINKER-MM4 trial show high response rates for linvoseltamab, offering new hope for newly diagnosed patients.
Advertisement
Robert Orlowski, M.D., Ph.D., shared the early effectiveness results from the phase 1 part of the LINKER-MM4 trial. He said the overall response rate was very high, and many patients had deep responses, even at this early stage of treatment.
He also discussed how linvoseltamab could fit into care for newly diagnosed patients. With several treatment options already available, he said linvoseltamab may become another strong choice, especially for patients who cannot receive other drugs or who may benefit from a targeted approach.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Health Begins at Home: Why Housing Has Become a Strategic Priority for Managed Care
2
Loss of copay assistance linked to worse outcomes in retina patients | ASRS 2026
3
Step therapy requirements drive up time, costs in DME patients | ASRS 2026
4
Intervention boosts connected insulin pen adoption among minorities with Type 1 diabetes
5


























